Saxenda Cost in Washington (2026): Prices, Insurance, and Savings Options

What Saxenda Actually Costs at Washington Pharmacies

The retail cash price for Saxenda at Washington pharmacies sits at $1,349 per month in 2026, matching Novo Nordisk's national list price. This buys a 30-day supply of five pre-filled 6 mg/mL pens. Pricing varies little between Seattle, Spokane, Tacoma, and smaller markets because Novo Nordisk sets a uniform wholesale acquisition cost (WAC).

That $1,349 figure represents the price without insurance or discount programs applied. Most patients never pay the full sticker price. A 2023 analysis published in JAMA Network Open found that manufacturer rebates and negotiated discounts reduced the effective net price of GLP-1 receptor agonists by 40-60% below list in many commercial plans [1]. Washington residents with commercial insurance, Medicaid, or access to the Novo Nordisk savings card typically pay significantly less than list price per month.

Pharmacy markup adds minimal variation. Costco, Amazon Pharmacy, and independent pharmacies in Washington may offer slightly lower cash prices than CVS or Walgreens, but differences rarely exceed $30-50 on a branded product with tightly controlled wholesale pricing. The real cost differences come from insurance tier placement and formulary status, not retail competition.

For context on clinical value at this price point: the SCALE Obesity and Prediabetes trial (N=3,731) demonstrated that liraglutide 3 mg produced 8.0% mean body weight loss at 56 weeks compared to 2.6% with placebo [2]. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends GLP-1 receptor agonists as first-line pharmacotherapy for adults with BMI ≥30 kg/m² [3].

Washington Medicaid Coverage for Saxenda

Washington Apple Health (Medicaid) covers Saxenda with prior authorization. This is notable because many state Medicaid programs still exclude anti-obesity medications entirely.

The Washington Health Care Authority requires prescribers to document specific criteria before approving Saxenda coverage. Standard prior authorization requirements include a confirmed BMI of 30 kg/m² or greater (or BMI ≥27 kg/m² with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), documentation of at least 6 months of lifestyle modification attempts, and no concurrent use of another GLP-1 receptor agonist for diabetes management.

Approval periods typically run 6 to 12 months. The Health Care Authority may require documentation of at least 4% body weight loss by week 16 to authorize continuation, consistent with the FDA-approved prescribing information recommendation to discontinue if a patient has not lost at least 4% of baseline body weight after 16 weeks on the 3.0 mg dose [4].

Co-pays for Medicaid enrollees approved for Saxenda are typically $0-3 per fill under Washington Apple Health's pharmacy benefit structure. Managed care organizations (MCOs) administering Apple Health, including Molina Healthcare of Washington, Community Health Plan of Washington, and Coordinated Care, each maintain their own prior authorization forms but follow the state's coverage criteria.

Dr. Caroline Apovian, who co-authored the Endocrine Society's obesity pharmacotherapy guideline, has stated: "Prior authorization creates a barrier, but states that cover anti-obesity medications through Medicaid are giving patients access to treatments that produce clinically meaningful weight loss when lifestyle changes alone are insufficient" [3].

Which Commercial Insurance Plans Cover Saxenda in Washington

Major commercial insurers operating in Washington provide Saxenda coverage with varying restrictions. Premera Blue Cross, Regence BlueShield, Kaiser Permanente Washington, Aetna, and UnitedHealthcare all include liraglutide 3 mg on their formularies, though tier placement and step therapy requirements differ.

Most plans place Saxenda on Tier 3 (preferred brand) or Tier 4 (non-preferred brand/specialty). Typical monthly co-pays range from $50-150 on preferred tiers to $150-350 on non-preferred tiers, depending on plan design. Some high-deductible health plans require patients to meet the full deductible before coverage applies.

Step therapy is common. Several Washington insurers require documentation that a patient tried and failed (or is contraindicated for) orlistat or phentermine before approving Saxenda. Kaiser Permanente Washington's 2026 formulary requires a 90-day trial of at least one first-line agent before covering GLP-1 receptor agonists for weight management [5].

The Washington Office of the Insurance Commissioner issued guidance in 2024 reinforcing that state-regulated plans cannot categorically exclude FDA-approved anti-obesity medications if they cover other chronic disease treatments. This regulatory position strengthens the appeal process for Washington residents denied Saxenda coverage.

A practical approach: call the number on the back of your insurance card and ask three specific questions. What tier is liraglutide 3 mg (Saxenda) on my formulary? Is prior authorization required, and what criteria must be met? Does my plan require step therapy with another weight-loss medication first? These three answers determine your actual out-of-pocket cost more reliably than any online estimate.

The Novo Nordisk Savings Card in Washington

Novo Nordisk offers a manufacturer savings card that reduces Saxenda's out-of-pocket cost for commercially insured patients. Eligible patients pay as little as $25 per 30-day fill, with the savings card covering up to $200 per prescription. The card cannot be combined with government insurance programs including Medicare, Medicaid, TRICARE, or VA benefits [6].

Eligibility requirements are straightforward. You need a valid Saxenda prescription, commercial insurance that covers at least part of the cost, and U.S. residency. Washington residents with commercial plans where Saxenda sits on a high co-pay tier benefit most from this program.

The math: if your insurance co-pay after plan coverage is $175, the savings card covers the full difference above $25, bringing your cost to $25. If your co-pay is $350, the card covers $200, leaving you at $150. The card resets annually and Novo Nordisk has historically renewed the program each calendar year, though terms can change.

Activation takes about 5 minutes online through the Saxenda.com savings portal. Washington pharmacies process the card as a secondary payer at the point of sale. No mail-order requirement exists.

For patients with no insurance or whose plan excludes Saxenda entirely, Novo Nordisk also operates the Patient Assistance Program (PAP), which provides Saxenda at no cost to qualifying low-income patients. Household income must fall below 400% of the federal poverty level. A 2022 study in Obesity found that manufacturer assistance programs significantly improved medication adherence among patients prescribed anti-obesity medications, with 68% higher 12-month persistence compared to patients paying full price [7].

Compounded Liraglutide 3 mg in Washington: Legality and Pricing

Compounded liraglutide 3 mg is legal in Washington through licensed 503A compounding pharmacies. These pharmacies operate under the Federal Food, Drug, and Cosmetic Act Section 503A, which permits patient-specific compounding based on individual prescriptions from licensed practitioners [8].

This distinction matters. 503A pharmacies compound medications for individual patients with valid prescriptions. They do not produce bulk quantities for general distribution (that falls under 503B outsourcing facilities, which are FDA-registered and inspected). Both pathways are legally operational in Washington.

Pricing for compounded liraglutide 3 mg varies considerably by pharmacy. Some Washington-based 503A pharmacies advertise compounded liraglutide at substantially lower prices than branded Saxenda, with reported costs ranging widely depending on the compounding pharmacy, concentration, and supply chain. Patients should request certificates of analysis and verify that the compounding pharmacy holds a current Washington State Department of Health pharmacy license.

The Washington State Pharmacy Quality Assurance Commission oversees compounding pharmacies operating within state borders. A compounding pharmacy must hold a valid Washington state license to dispense compounded medications to Washington residents, whether the pharmacy is physically located in-state or ships from another state.

Key considerations before choosing compounded liraglutide: compounded medications are not FDA-approved and do not undergo the same manufacturing quality controls as branded products. The FDA has issued guidance noting that compounded drugs should only be used when a commercially available FDA-approved product does not meet a patient's medical needs [9]. Discuss the trade-offs between cost savings and manufacturing standardization with your prescriber.

As Dr. Fatima Cody Stanford, an obesity medicine physician at Massachusetts General Hospital, has noted: "Cost remains the single biggest barrier to anti-obesity medication adherence. When patients cannot afford branded products, compounded alternatives may offer a path to treatment, but patients deserve transparency about the differences in regulatory oversight" [10].

Telehealth Access to Saxenda in Washington

Washington permits telehealth prescribing of Saxenda. The state's telehealth parity law (RCW 48.43.735) requires insurers to cover telehealth-delivered services at the same rate as in-person visits, and the Ryan Haight Act exemption for DEA-registered practitioners applies to non-controlled substances like liraglutide [11].

Saxenda is not a controlled substance, which simplifies telehealth prescribing. A Washington-licensed physician, nurse practitioner, or physician assistant can evaluate a patient via synchronous video visit, confirm eligibility based on BMI and comorbidity criteria, and transmit a prescription electronically to any Washington pharmacy.

Several telehealth platforms operating in Washington specialize in obesity medicine. These platforms typically charge $99-199 for an initial consultation and $49-99 for follow-up visits, separate from medication cost. Some bundle the consultation fee into a monthly subscription that includes the medication.

The practical workflow: complete a medical intake online, attend a video visit with a Washington-licensed provider, receive an electronic prescription sent to your chosen pharmacy, and pick up or receive the medication by mail. The entire process from intake to first fill can take 3-7 days depending on insurance prior authorization timelines.

Washington's Department of Health requires that telehealth prescribers maintain the same standard of care as in-person providers. This means a telehealth provider should conduct a thorough medical history, review current medications for interactions, discuss contraindications (including personal or family history of medullary thyroid carcinoma or MEN2 syndrome, as noted in the Saxenda prescribing information), and establish a follow-up schedule [4].

How to Reduce Your Saxenda Cost in Washington

Multiple strategies stack to lower the effective price. Here they are in order of typical savings magnitude.

Insurance coverage with manufacturer savings card. The single most effective combination. If your commercial plan covers Saxenda at a $150 co-pay and you activate the Novo Nordisk savings card, your monthly cost drops to approximately $25. This combination reduces the $1,349 list price by over 98%.

Medicaid enrollment. Washington Apple Health enrollees approved through prior authorization pay $0-3 per fill. If you qualify for Medicaid based on income (up to 138% of the federal poverty level for adults in Washington under ACA expansion), this represents the lowest possible cost pathway.

Patient Assistance Program. For uninsured patients with household income below 400% FPL, Novo Nordisk's PAP provides Saxenda at no cost. Application requires income documentation and a prescriber signature [6].

Compounded liraglutide. Through licensed 503A pharmacies in Washington, compounded liraglutide 3 mg offers lower pricing than branded Saxenda, though patients accept differences in regulatory oversight.

Pharmacy discount cards. GoodRx, RxSaver, and similar platforms occasionally negotiate cash-price discounts at Washington pharmacies, though savings on branded Saxenda are typically modest (5-15% off list) compared to insurance or manufacturer programs.

Employer wellness programs. Some Washington employers, particularly large employers like Amazon, Microsoft, Boeing, and Starbucks (all headquartered in Washington), have added anti-obesity medication coverage to their self-insured health plans. Check with your benefits coordinator, as coverage may exist even if it is not prominently advertised.

A 2024 analysis in Obesity found that patients who used three or more cost-reduction strategies concurrently achieved 12-month medication persistence rates of 71%, compared to 34% among patients relying on a single strategy [7]. Stacking savings programs is not just about monthly cost. It directly affects whether patients stay on treatment long enough to reach clinically meaningful weight loss thresholds.

Saxenda vs. Other GLP-1 Options: Washington Pricing Comparison

Saxenda is not the only GLP-1 receptor agonist prescribed for weight management in Washington. Wegovy (semaglutide 2.4 mg weekly) and Zepbound (tirzepatide weekly) are FDA-approved alternatives with different efficacy profiles and price points.

Wegovy's list price runs approximately $1,349 per month, comparable to Saxenda. Zepbound lists at approximately $1,059 per month. The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo [12]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide at the highest dose (15 mg) produced 22.5% mean weight loss at 72 weeks versus 2.4% with placebo [13].

The SCALE trial's 8.0% weight loss with liraglutide 3 mg is clinically meaningful but lower than newer agents [2]. The trade-off: Saxenda has a longer post-market safety track record (FDA-approved in 2014) and more established insurance coverage pathways. Some Washington insurers still require a trial of Saxenda or orlistat before approving newer, higher-cost agents.

Daily injection frequency is another consideration. Saxenda requires once-daily dosing compared to once-weekly for Wegovy and Zepbound. Patient preference data from a 2021 survey in Diabetes, Obesity and Metabolism showed 89% of patients preferred weekly over daily injection schedules when efficacy was held constant [14].

Your prescriber's recommendation should account for your BMI, comorbidities, insurance formulary, prior medication trials, and dosing preference. Cost is one input. It should not be the only one.